U.S. manufacturing sites and capabilities
Manufacturing throughout the U.S. with a commitment to quality, innovation,
and reliability
Global pressures don’t pause for complexity. If your manufacturing strategy can’t shift with the market, momentum slips away.
Thermo Fisher Scientific’s U.S. infrastructure is built to keep pace—advancing programs from a single molecule to a global portfolio, across every stage of development.
U.S.-based infrastructure
built for resilience
Our strategically located, FDA-inspected facilities across the U.S. help ensure scalable, phase-appropriate manufacturing solutions—from early development through first-in-human trials to commercial supply.
These sites are designed to reduce risk, speed transitions, and help keep your program moving—no matter the external pressures.
Connected supply chains and custom continuity planning
You gain supply chain assurance and flexibility through supplier diversification, strategic sourcing, foreign trade zones, and tailored logistics planning. Our teams work with you to develop continuity strategies that align with your business and regulatory needs.
Learn more about our
pharma supply chain solutions.
Access the advantages of
Foreign Trade Zones (FTZs)
We currently operate four active FTZs at:
High Point, North Carolina
Cincinnati, Ohio
Manatí, Puerto Rico
Florence East, SC
Key advantages include:
- Imported materials not subject to duties when final product is exported
- Legal import of commercial pharmaceuticals prior to FDA approval
- Duty deferral, which could assist with cash liquidity issues
We’re planning additional zones across the U.S. by 2026 to expand these benefits even further.
Seamless transition from development to
commercial production
This policy is supported by cross-functional teams and harmonized processes. With built-in checkpoints for quality and performance, you gain a smoother path from development through launch—whether staying within the U.S. or transferring from global sites.
Financial flexibility built to support early-phase momentum
We offer extended terms agreements tailored to the needs of clinical programs, helping you manage resources during early development. Typical agreements range from 6 to 12 months, with options for further extension based on project milestones.
Investing in what’s next—for the U.S. and for our partners
Thermo Fisher is investing $2 billion over the next four years to expand innovation, infrastructure, and capacity across our U.S. network:
- $1.5 billion in capital improvements to grow U.S.
manufacturing operations - $500 million in R&D focused on accelerating high-impact
technologies and capabilities
“Thermo Fisher’s commitment to U.S. manufacturing reflects our confidence that America will continue to lead the world in science and innovation. By expanding our U.S. operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come.”
— Marc N. Casper, Chairman, President, and CEO, Thermo Fisher Scientific (April 24, 2025)
Our unique global scale and depth across the U.S.
{{ item.title }}
{{ totalVisibleMarkers }} Results found
{{ regionGroup.regionName }}